Consensus report from the 6th International forum for liver MRI using gadoxetic acid

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/108276/1/jmri24419.pd

Diseases of the Abdomen and Pelvis 2018-2021: Diagnostic Imaging - IDKD Book

Gastrointestinal disease; PET/CT; Radiology; X-ray; IDKD; Davo

Proceedings of the International Cancer Imaging Society (ICIS) 16th Annual Teaching Course

Table of contents O1 Tumour heterogeneity: what does it mean? Dow-Mu Koh O2 Skeletal sequelae in adult survivors of childhood cancer Sue Creviston Kaste O3 Locoregional effects of breast cancer treatment Sarah J Vinnicombe O4 Imaging of cancer therapy-induced CNS toxicity Giovanni Morana, Andrea Rossi O5 Screening for lung cancer Christian J. Herold O6Risk stratification of lung nodules Theresa C. McLoud O7 PET imaging of pulmonary nodules Kirk A Frey O8 Transarterial tumour therapy Bernhard Gebauer O9 Interventional radiology in paediatric oncology Derek Roebuck O10 Image guided prostate interventions Jurgen J. Fütterer O11 Imaging cancer predisposition syndromes Alexander J. Towbin O12Chest and chest wall masses Thierry AG Huisman O13 Abdominal masses: good or bad? Anne MJB Smets O14 Hepatobiliary MR contrast: enhanced liver MRI for HCC diagnosis and management Giovanni Morana O15 Role of US elastography and multimodality fusion for managing patients with chronic liver disease and HCC Jeong Min Lee O16 Opportunities and challenges in imaging metastatic disease Hersh Chandarana O17 Diagnosis, treatment monitoring, and follow-up of lymphoma Marius E. Mayerhoefer, Markus Raderer, Alexander Haug O18 Managing high-risk and advanced prostate cancer Matthias Eiber O19 Immunotherapy: imaging challenges Bernhard Gebauer O20 RECIST and RECIST 1.1 Andrea Rockall O21 Challenges of RECIST in oncology imaging basics for the trainee and novice Aslam Sohaib O22 Lymphoma: PET for interim and end of treatment response assessment: a users’ guide to the Deauville Score Victoria S Warbey O23 Available resources Hebert Alberto Vargas O24 ICIS e-portal and the online learning community Dow-Mu Koh O25 Benign lesions that mimic pancreatic cancer Jay P Heiken O26 Staging and reporting pancreatic malignancies Isaac R Francis, Mahmoud, M Al-Hawary, Ravi K Kaza O27 Intraductal papillary mucinous neoplasm Giovanni Morana O28 Cystic pancreatic tumours Mirko D’Onofrio O29 Diffusion-weighted imaging of head and neck tumours Harriet C. Thoeny O30 Radiation injury in the head and neck Ann D King O31 PET/MR of paediatric brain tumours Giovanni Morana, Arnoldo Piccardo, Maria Luisa Garrè, Andrea Rossi O32 Structured reporting and beyond Hebert Alberto Vargas O33 Massachusetts General Hospital experience with structured reporting Theresa C. McLoud O34 The oncologist’s perspective: what the oncologist needs to know Nick Reed O35 Towards the cure of all children with cancer: global initiatives in pediatric oncology Carlos Rodriguez-Galindo O36 Multiparametric imaging of renal cancers Hersh Chandarana O37 Linking imaging features of renal disease and their impact on management strategies Hebert Alberto Vargas O38 Adrenals, retroperitoneum and peritoneum Isaac R Francis, Ashish P Wasnik O39 Lung and pleura Stefan Diederich O40 Advances in MRI Jurgen J. Fütterer O41 Advances in molecular imaging Wim J.G. Oyen O42 Incorporating advanced imaging, impact on treatment selection and patient outcome Cheng Lee Chaw, Nicholas van As S1 Combining ADC-histogram features improves performance of MR diffusion-weighted imaging for Lymph node characterisation in cervical cancer Igor Vieira, Frederik De Keyzer, Elleke Dresen, Sileny Han, Ignace Vergote, Philippe Moerman, Frederic Amant, Michel Koole, Vincent Vandecaveye S2 Whole-body diffusion-weighted MRI for surgical planning in patients with colorectal cancer and peritoneal metastases R Dresen, S De Vuysere, F De Keyzer, E Van Cutsem, A D’Hoore, A Wolthuis, V Vandecaveye S3 Role of apparent diffusion coefficient (ADC) diffusion-weighted MRI for predicting extra capsular extension of prostate cancer. P. Pricolo ([email protected]), S. Alessi, P. Summers, E. Tagliabue, G. Petralia S4 Generating evidence for clinical benefit of PET/CT – are management studies sufficient as surrogate for patient outcome? C. Pfannenberg, B. Gückel, SC Schüle, AC Müller, S. Kaufmann, N. Schwenzer, M. Reimold,C. la Fougere, K. Nikolaou, P. Martus S5 Heterogeneity of treatment response in skeletal metastases from breast cancer with 18F-fluoride and 18F-FDG PET GJ Cook, GK Azad, BP Taylor, M Siddique, J John, J Mansi, M Harries, V Goh S6 Accuracy of suspicious breast imaging—can we tell the patient? S Seth, R Burgul, A Seth S7 Measurement method of tumour volume changes during neoadjuvant chemotherapy affects ability to predict pathological response S Waugh, N Muhammad Gowdh, C Purdie, A Evans, E Crowe, A Thompson, S Vinnicombe S8 Diagnostic yield of CT IVU in haematuria screening F. Arfeen, T. Campion, E. Goldstraw S9 Percutaneous radiofrequency ablation of unresectable locally advanced pancreatic cancer: preliminary results D’Onofrio M, Ciaravino V, Crosara S, De Robertis R, Pozzi Mucelli R S10 Iodine maps from dual energy CT improve detection of metastases in staging examinations of melanoma patients M. Uhrig, D. Simons, H. Schlemmer S11Can contrast enhanced CT predict pelvic nodal status in malignant melanoma of the lower limb? Kate Downey S12 Current practice in the investigation for suspected Paraneoplastic Neurological Syndromes (PNS) and positive malignancy yield. S Murdoch, AS Al-adhami, S Viswanathan P1 Technical success and efficacy of Pulmonary Radiofrequency ablation: an analysis of 207 ablations S Smith, P Jennings, D Bowers, R Soomal P2 Lesion control and patient outcome: prospective analysis of radiofrequency abaltion in pulmonary colorectal cancer metastatic disease S Smith, P Jennings, D Bowers, R Soomal P3 Hepatocellular carcinoma in a post-TB patient: case of tropical infections and oncologic imaging challenges TM Mutala, AO Odhiambo, N Harish P4 Role of apparent diffusion coefficient (ADC) diffusion-weighted MRI for predicting extracapsular extension of prostate cancer P. Pricolo, S. Alessi, P. Summers, E. Tagliabue, G. Petralia P5 What a difference a decade makes; comparison of lung biopsies in Glasgow 2005 and 2015 M. Hall, M. Sproule, S. Sheridan P6 Solid pseudopapillary tumour of pancreas: imaging features of a rare neoplasm KY Thein, CH Tan, YL Thian, CM Ho P7 MDCT - pathological correlation in colon adenocarcinoma staging: preliminary experience S De Luca, C Carrera, V Blanchet, L Alarcón, E Eyheremnedy P8 Image guided biopsy of thoracic masses and reduction of pneumothorax risk: 25 years experience B K Choudhury, K Bujarbarua, G Barman P9 Tumour heterogeneity analysis of 18F-FDG-PET for characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 GJ Cook, E Lovat, M Siddique, V Goh, R Ferner, VS Warbey P10 Impact of introduction of vacuum assisted excision (VAE) on screen detected high risk breast lesions L Potti, B Kaye, A Beattie, K Dutton P11 Can we reduce prevalent recall rate in breast screening? AA Seth, F Constantinidis, H Dobson P12 How to reduce prevalent recall rate? Identifying mammographic lesions with low Positive Predictive Value (PPV) AA Seth ([email protected]), F Constantinidis, H Dobson P13 Behaviour of untreated pulmonary thrombus in oncology patients diagnosed with incidental pulmonary embolism on CT R. Bradley, G. Bozas, G. Avery, A. Stephens, A. Maraveyas P14 A one-stop lymphoma biopsy service – is it possible? S Bhuva, CA Johnson, M Subesinghe, N Taylor P15 Changes in the new TNM classification for lung cancer (8th edition, effective January 2017) LE Quint, RM Reddy, GP Kalemkerian P16 Cancer immunotherapy: a review of adequate imaging assessment G González Zapico, E Gainza Jauregui, R Álvarez Francisco, S Ibáñez Alonso, I Tavera Bahillo, L Múgica Álvarez P17 Succinate dehydrogenase mutations and their associated tumours O Francies, R Wheeler, L Childs, A Adams, A Sahdev P18 Initial experience in the usefulness of dual energy technique in the abdomen SE De Luca, ME Casalini Vañek, MD Pascuzzi, T Gillanders, PM Ramos, EP Eyheremendy P19 Recognising the serious complication of Richter’s transformation in CLL patients C Stove, M Digby P20 Body diffusion-weighted MRI in oncologic practice: truths, tricks and tips M. Nazar, M. Wirtz, MD. Pascuzzi, F. Troncoso, F. Saguier, EP. Eyheremendy P21 Methotrexate-induced leukoencephalopathy in paediatric ALL Patients D.J. Quint, L. Dang, M. Carlson, S. Leber, F. Silverstein P22 Pitfalls in oncology CT reporting. A pictorial review R Rueben, S Viswanathan P23 Imaging of perineural extension in head and neck tumours B Nazir, TH Teo, JB Khoo P24 MRI findings of molecular subtypes of breast cancer: a pictorial primer K Sharma, N Gupta, B Mathew, T Jeyakumar, K Harkins P25 When cancer can’t wait! A pictorial review of oncological emergencies K Sharma, B Mathew, N Gupta, T Jeyakumar, S Joshua P26 MRI of pancreatic neuroendocrine tumours: an approach to interpretation D Christodoulou, S Gourtsoyianni, A Jacques, N Griffin, V Goh P27 Gynaecological cancers in pregnancy: a review of imaging CA Johnson, J Lee P28 Suspected paraneoplastic neurological syndromes - review of published recommendations to date, with proposed guideline/flowchart JA Goodfellow, AS Al-adhami, S Viswanathan P29 Multi-parametric MRI of the pelvis for suspected local recurrence of prostate cancer after radical prostatectomy R Bradley P30 Utilisation of PI-RADS version 2 in multi-parametric MRI of the prostate; 12-months experience R Bradley P31 Radiological assessment of the post-chemotherapy liver A Yong, S Jenkins, G Joseph P32 Skeletal staging with MRI in breast cancer – what the radiologist needs to know S Bhuva, K Partington P33 Perineural spread of lympoma: an educational review of an unusual distribution of disease CA Johnson, S Bhuva, M Subesinghe, N Taylor P34 Visually isoattenuating pancreatic adenocarcinoma. Diagnostic imaging tools. C Carrera, A Zanfardini, S De Luca, L Alarcón, V Blanchet, EP Eyheremendy P35 Imaging of larynx cancer: when is CT, MRI or FDG PET/CT the best test? K Cavanagh, E Lauhttp://deepblue.lib.umich.edu/bitstream/2027.42/134651/1/40644_2016_Article_79.pd

Hepatozelluläres Karzinom: Etablierung bildbasierter Biomarker für nicht-invasive Subtypendifferenzierung mittels Gd-EOB-verstärktem MRT

Background: Hepatocellular carcinoma (HCC) exhibits highly diverse phenotypes, thus complicating diagnostics and prediction of response to therapy. The World Health Organization (WHO) now defines eight subtypes, potentially advancing precision oncology in HCC. However, diagnosing these subtypes typically requires invasive procedures. To explore a non-invasive alternative, we investigated whether imaging features in magnetic resonance imaging (MRI) enhanced with gadoxetic acid (Gd-EOB) are associated with these subtypes. Methods: We retrospectively included 240 consecutive patients with 262 histopathologically confirmed HCC lesions who underwent surgical resection or liver transplantation at our center from January 2010 to January 2022 and received preoperative Gd-EOB MRI. Two pathologists assigned subtypes to the specimens. Subsequently, two radiologists assessed qualitative and quantitative imaging features in Gd-EOB MRI, and we analyzed their distribution among subtypes. Diagnostic tests were formulated for each subtype, and their performance was evaluated. Results: The typical enhancement pattern for HCC is common in “Not otherwise specified” (NOS) HCC (88/168, 52%) and uncommon in macrotrabecular massive (MTM) (3/15, 20%), scirrhous (SC) (2/9, 22%) and chromophobe (CH) HCC (1/8, 13%) (p=0.035). MTM-HCC was associated with macrovascular invasion (5/16, 31%) (p=0.033) and high AFP (median, 397 μg/l (74-5370))(p48 μg/l and atypical enhancement has 25% sensitivity (SEN), 99% specificity (SPE), 75% positive predictive value (PPV), and 25 positive likelihood ratio (PLR). For ST-HCC, intralesional steatosis with diabetes type II has 54% SEN, 96% SPE, 67% PPV and 13.5 PLR. For FIB-HCC, age <60 with no risk factors has 80% SEN, 100% SPE and 100% PPV. High intralesional Gd-EOB uptake area over 50%, while not significantly different across all subtypes, was exclusive to NOS-HCC (16/174, 9%), CC-HCC (3/13, 23%) and ST-HCC (3/33, 9%)(p=0.031 in post-hoc analysis). Conclusion: Gd-EOB-enhanced MRI is of value in suggesting or ruling out specific subtypes, notably MTM-HCC and ST-HCC. A valuable clinical application could be to identify patients who would benefit from biopsy. Hepatobiliary phase iso- to hyperintensity is uncommon and indicates subtypes with a better prognosis. Further research is essential to better characterize NOS-HCC and uncommon subtypes, validate predictors, and to investigate the clinical impact of strategies incorporating WHO subtypes of HCC.Hintergrund: Das hepatozelluläre Karzinom (HCC) stellt sich äußerst vielfältig dar, wodurch Diagnostik und die Vorhersage des therapeutischen Ansprechens erschwert werden. Die Weltgesundheitsorganisation (WHO) definiert nun acht Subtypen, die den Weg für eine präzisere Onkologie bereiten könnten, aber invasive Diagnostik voraussetzen. Wir untersuchten, ob Bildmerkmale in der mit Gadoxetsäure (Gd-EOB) verstärkten Magnetresonanztomographie (MRT) mit Subtypen assoziiert sind. Methoden: Wir haben retrospektiv 240 aufeinanderfolgende Patienten mit 262 histologisch gesicherten HCCs eingeschlossen, die sich an unserem Zentrum zwischen Januar 2010 und Januar 2022 einer chirurgischen Resektion oder Lebertransplantation unterzogen und bei denen präoperative Gd-EOB MRT-Bildstudien vorlagen. Subtypen wurden durch zwei Pathologen zugeordnet. Qualitative und quantitative Bildmerkmale wurden durch zwei Radiologen erhoben und zwischen den Subtypen verglichen. Wir entwickelten diagnostische Tests für die Subtypen und evaluierten deren diagnostische Genauigkeit. Ergebnisse: Das HCC-typische Anreicherungsmuster trat häufiger in „Nicht genauer angegeben“ (NOS) HCC (88/168, 52%) auf und seltener in makrotrabekulär massivem (MTM) (3/15, 20%), szirrhösem (SC) (2/9, 22%) und chromophobem (CH) HCC (1/8, 13%) (p=0.035). MTM-HCC war mit makrovaskulärer Infiltration, (5/16, 31%) (p=0.033) und hohem AFP-Wert assoziiert (Median, 397 μg/l (74-5370)) (p48 μg/l und atypischem Anreicherungsmuster 25% Sensitivität (SEN), 99% Spezifizität (SPE), 75% positiv prädiktiven Wert (PPV) und 25 positives Likelihood Ratio (PLR). Für ST-HCC hatten intraläsionale Steatose mit Diabetes Typ II 54% SEN, 96% SPE, 67% PPV und 13.5 PLR. Für FIB-HCC hatten Alter <60 ohne Risikofaktoren 80% SEN, 100% SPE und 100% PPV. Hohe intraläsionale Gd-EOB-Aufnahmefläche über 50%, obwohl nicht signifikant unterschiedlich, trat ausschließlich bei NOS-HCC (16/174, 9%), CC-HCC (3/13, 23%) und ST-HCC (3/33, 9%) auf (p=0.031 in der Post-hoc-Analyse). Konklusion: Gd-EOB-verstärkte MRT ist für die Bestimmung der HCC-Subtypen von Mehrwert, insbesondere für MTM-HCC und ST-HCC. Dadurch könnten u.a. Patienten identifiziert werden, die von einer Biopsie profitieren. Iso- bis Hyperintensität in der hepatobiliären Phase ist selten und identifiziert Subtypen mit einer besseren Prognose. Weitere Forschung ist erforderlich, um NOS-HCC und seltene Subtypen genauer zu charakterisieren, Prädiktoren zu validieren und die klinische Auswirkung von Strategien, die auf den WHO-Subtypen beruhen, zu untersuchen

Advances in liver US, CT, and MRI: moving toward the future

Over the past two decades, the epidemiology of chronic liver disease has changed with an increase in the prevalence of nonalcoholic fatty liver disease in parallel to the advent of curative treatments for hepatitis C. Recent developments provided new tools for diagnosis and monitoring of liver diseases based on ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), as applied for assessing steatosis, fibrosis, and focal lesions. This narrative review aims to discuss the emerging approaches for qualitative and quantitative liver imaging, focusing on those expected to become adopted in clinical practice in the next 5 to 10 years. While radiomics is an emerging tool for many of these applications, dedicated techniques have been investigated for US (controlled attenuation parameter, backscatter coefficient, elastography methods such as point shear wave elastography [pSWE] and transient elastography [TE], novel Doppler techniques, and three-dimensional contrast-enhanced ultrasound [3D-CEUS]), CT (dual-energy, spectral photon counting, extracellular volume fraction, perfusion, and surface nodularity), and MRI (proton density fat fraction [PDFF], elastography [MRE], contrast enhancement index, relative enhancement, T1 mapping on the hepatobiliary phase, perfusion). Concurrently, the advent of abbreviated MRI protocols will help fulfill an increasing number of examination requests in an era of healthcare resource constraints

State of the Art in Artificial Intelligence and Radiomics in Hepatocellular Carcinoma

The most common liver malignancy is hepatocellular carcinoma (HCC), which is also associated with high mortality. Often HCC develops in a chronic liver disease setting, and early diagnosis as well as accurate screening of high-risk patients is crucial for appropriate and effective management of these patients. While imaging characteristics of HCC are well-defined in the diagnostic phase, challenging cases still occur, and current prognostic and predictive models are limited in their accuracy. Radiomics and machine learning (ML) offer new tools to address these issues and may lead to scientific breakthroughs with the potential to impact clinical practice and improve patient outcomes. In this review, we will present an overview of these technologies in the setting of HCC imaging across different modalities and a range of applications. These include lesion segmentation, diagnosis, prognostic modeling and prediction of treatment response. Finally, limitations preventing clinical application of radiomics and ML at the present time are discussed, together with necessary future developments to bring the field forward and outside of a purely academic endeavor

Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.

ObjectivesThe 8th International Forum for Liver Magnetic Resonance Imaging (MRI), held in Basel, Switzerland, in October 2017, brought together clinical and academic radiologists from around the world to discuss developments in and reach consensus on key issues in the field of gadoxetic acid-enhanced liver MRI since the previous Forum held in 2013.MethodsTwo main themes in liver MRI were considered in detail at the Forum: the use of gadoxetic acid for contrast-enhanced MRI in patients with liver cirrhosis and the technical performance of gadoxetic acid-enhanced liver MRI, both opportunities and challenges. This article summarises the expert presentations and the delegate voting on consensus statements discussed at the Forum.Results and conclusionsIt was concluded that gadoxetic acid-enhanced MRI has higher sensitivity for the diagnosis of hepatocellular carcinoma (HCC), when compared with multidetector CT, by utilising features of hyperenhancement in the arterial phase and hypointensity in the hepatobiliary phase (HBP). Recent HCC management guidelines recognise an increasing role for gadoxetic acid-enhanced MRI in early diagnosis and monitoring post-resection. Additional research is needed to define the role of HBP in predicting microvascular invasion, to better define washout during the transitional phase in gadoxetic acid-enhanced MRI for HCC diagnosis, and to reduce the artefacts encountered in the arterial phase. Technical developments are being directed to shortening the MRI protocol for reducing time and patient discomfort and toward utilising faster imaging and non-Cartesian free-breathing approaches that have the potential to improve multiphasic dynamic imaging.Key points• Gadoxetic acid-enhanced MRI provides higher diagnostic sensitivity than CT for diagnosing HCC. • Gadoxetic acid-enhanced MRI has roles in early-HCC diagnosis and monitoring post-resection response. • Faster imaging and free-breathing approaches have potential to improve multiphasic dynamic imaging

State-of-the-art MR imaging in the work-up of primary hepatocellular tumors

Magnetic resonance (MR) imaging is an imaging modality that has evolved rapidly in the past two decades. The development of advanced hardware and new sophisticated pulse sequences have allowed faster imaging, with increased temporal and spatial resolution. This has resulted in the development and implementation of new acquisition techniques that facilitate improved visualisation of neoplastic processes. In addition, faster sequences enable multiphasic dynamic imaging after intravenous administration of contrast material, which results in better tumor characterisation and improved diagnostic confidence by the reading radiologist. The radiol